Literature DB >> 22415423

Congruence of primary brain tumor patient and caregiver symptom report.

Terri S Armstrong1, Jeffrey S Wefel, Ibrahima Gning, Alvina Acquaye, Elizabeth Vera-Bolanos, Mark R Gilbert, Charles S Cleeland, Tito Mendoza.   

Abstract

BACKGROUND: Evaluating the severity of symptoms in patients with primary brain tumors (PBTs) is important in clinical care and research but may be difficult due to patient neurocognitive (NC) impairment. This study was conducted to evaluate the congruence of symptom reporting in patient and caregiver dyads, examining potential impact of NC impairment and Karnofsky performance status (KPS).
METHODS: PBT patients undergoing NC testing and their caregivers were included in this study. These dyads (paired patient and caregiver group) completed the MD Anderson Symptom Inventory-Brain Tumor Module prior to testing, and impairment was categorized based on NC test scores. Concordance and equivalency was then assessed using Bland-Altman analysis and 2 one-sided techniques.
RESULTS: A total of 115 dyads participated. Median patient and caregiver age was 49 and 51 years, respectively, and 63% of patients were male (73% female caregivers). Most patients had a good KPS (≥90, 66%) but were classified as NC impaired (58%). Caregiver's report of patient symptoms are congruent to the self-report of the patient. Equivalency between patient and caregiver report were found using prespecified confidence intervals. KPS group (good, ≥90; poor, ≤80) comparisons of equivalency indicated no significant differences in symptoms and interference reporting between dyads (good = 0.49, P > .05; and poor = 0.3, P > .05) overall, but there was a tendency for higher report by caregivers if the patients had a poor KPS.
CONCLUSIONS: Caregivers of PBT patients have similar assessments of symptom severity (highly congruent) with patient self-report regardless of NC function or KPS. These findings suggest that caregivers may serve as proxy report of symptoms for primary brain tumor patients.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Year:  2012        PMID: 22415423     DOI: 10.1002/cncr.27483

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden.

Authors:  Daniel I Jacobs; Priya Kumthekar; Becky V Stell; Sean A Grimm; Alfred W Rademaker; Laurie Rice; James P Chandler; Kenji Muro; MaryAnne Marymont; Irene B Helenowski; Lynne I Wagner; Jeffrey J Raizer
Journal:  Neurooncol Pract       Date:  2014-05-05

2.  Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials.

Authors:  Terri S Armstrong
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

Review 3.  Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).

Authors:  Jennifer L Helfer; Patrick Y Wen; Jaishri Blakeley; Mark R Gilbert; Terri S Armstrong
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

Review 4.  Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Authors:  Jaishri O Blakeley; Stephen Joel Coons; John R Corboy; Nancy Kline Leidy; Tito R Mendoza; Jeffrey S Wefel
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

5.  Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module.

Authors:  Shota Tanaka; Iori Sato; Masamichi Takahashi; Terri S Armstrong; Charles S Cleeland; Tito R Mendoza; Akitake Mukasa; Shunsaku Takayanagi; Yoshitaka Narita; Kiyoko Kamibeppu; Nobuhito Saito
Journal:  Jpn J Clin Oncol       Date:  2020-07-09       Impact factor: 3.019

6.  The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms.

Authors:  Terri S Armstrong; Elizabeth Vera-Bolanos; Alvina A Acquaye; Mark R Gilbert; Harshad Ladha; Tito Mendoza
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

7.  The Brain Metastases Symptom Checklist as a novel tool for symptom measurement in patients with brain metastases undergoing whole-brain radiotherapy.

Authors:  D Rodin; B Banihashemi; L Wang; A Lau; S Harris; W Levin; R Dinniwell; B A Millar; C Chung; N Laperriere; A Bezjak; R K S Wong
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

8.  Primary brain tumor patients' supportive care needs and multidisciplinary rehabilitation, community and psychosocial support services: awareness, referral and utilization.

Authors:  Danette Langbecker; Patsy Yates
Journal:  J Neurooncol       Date:  2015-12-07       Impact factor: 4.130

9.  Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module.

Authors:  Karin Piil; Meagan Whisenant; Tito Mendoza; Terri Armstrong; Charles Cleeland; Sara Nordentoft; Loretta A Williams; Mary Jarden
Journal:  Neurooncol Pract       Date:  2020-10-19

10.  Subjective executive dysfunction in patients with primary brain tumors and their informants: relationships with neurocognitive, psychological, and daily functioning.

Authors:  Sarah Ellen Braun; Autumn Lanoye; Farah J Aslanzadeh; Ashlee R Loughan
Journal:  Brain Inj       Date:  2021-12-07       Impact factor: 2.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.